Op-Ed

PrintPrint EmailEmail ShareShare CiteCite
Style:MLAAPAChicagoClose

loading...

Sometimes Brand-Name Drugs Really Are Better

Author: Peter R. Orszag, Adjunct Senior Fellow
April 22, 2014
Bloomberg.com

Share

When you go to the pharmacy for aspirin, do you buy Bayer or the private-label generic alternative offered by chains such as CVS? The price for Bayer's version is more than twice that of CVS's, yet the active ingredient is exactly the same. The choice may seem trivial, but it provides insight into larger economic and health questions.

Research by Matthew Gentzkow of the University of Chicago -- who last week won the prestigious John Bates Clark prize for the best young economist in the U.S. -- and co-authors studied exactly this question. They estimate that U.S. consumers would save $32 billion a year by switching to generic labels for goods (not just aspirin) that are equivalent to their brand-name alternatives.

Gentzkow and colleagues used data from the Nielsen Homescan Consumer Panel, which gave households optical scanners to record the barcodes of all packaged goods they bought, and surveyed additional household characteristics. They found that generics accounted for 71 percent of all headache pills purchased (including aspirin, ibuprofen and related products) and 49 percent of the dollars spent on those pills.

View full text of article.

More on This Topic

Expert Brief

The G20's Continuing Policy Drift

Author: Steven Dunaway

Instead of addressing serious problems in global imbalances, the February 18-19 meeting of the G20 finance minister is poised to go astray...

Expert Brief

The G20 Summit's Lost Focus

Author: Steven Dunaway

The Fed's decision to resume quantitative easing will likely shift the focus of the G20 summit and make it harder to settle currency-policy...

Video

The G8 Summit: Three Things to Know

Speaker: Terra Lawson-Remer

The G8 meeting at Camp David will focus on food security and advancing political transitions in the Middle East and North Africa, while the...